Abstract: Cyclosporin A (CsA) is a natural macrocyclic compound traditionally utilized as a potent immunosuppressant. Recently, its pharmacological profile has garnered significant interest in the field of neuroprotection and brain injury. Based on the provided literature, CsA acts as a pan-cyclophilin inhibitor. While its immunosuppressive properties stem from the inhibition of the calcineurin-NFAT pathway via binding to Cyclophilin A (CypA) and Cyclophilin B (CypB), its neuroprotective effects are primarily mediated through the inhibition of mitochondrial Cyclophilin D (CypD). By targeting CypD, CsA prevents the opening of the mitochondrial permeability transition pore (mPTP), a critical event triggered by calcium overload and reactive oxygen species (ROS) during cerebral ischemia-reperfusion injury and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). Furthermore, CsA and its derivatives mitigate neuroinflammation by blocking extracellular CypA. Despite its therapeutic potential, the clinical application of CsA for neuroprotection is hindered by its immunosuppressive side effects, nephrotoxicity, poor physicochemical properties, and restricted transport across the blood-brain barrier (BBB) by P-glycoprotein. Current research focuses on developing non-immunosuppressive, isoform-selective, and BBB-permeable cyclophilin inhibitors to safely harness these neuroprotective mechanisms.
1. Introduction
Cyclosporin A (CsA) is a well-known natural macrocyclic peptide that was originally identified for its high affinity to a family of ubiquitous cellular proteins called cyclophilins (Cyps), which possess peptidyl-prolyl cis-trans isomerase (PPIase) activity [1]. For decades, CsA has been a cornerstone in transplantation medicine and the treatment of autoimmune disorders due to its potent immunosuppressive capabilities [2]. However, emerging research has highlighted the critical role of cyclophilins in various pathophysiological conditions beyond the immune system, including viral infections, cardiovascular diseases, and neurodegeneration [1].
In the context of neuroprotection and brain injury, the focus has shifted toward the ability of CsA to inhibit specific cyclophilin isoforms, most notably the mitochondrial Cyclophilin D (CypD) and extracellular Cyclophilin A (CypA). Through these interactions, CsA demonstrates significant potential in preserving mitochondrial integrity, preventing necrotic and apoptotic cell death, and reducing neuroinflammation following cerebral insults and in progressive neurodegenerative states [1].
2. Pharmacological Activity
The pharmacological activity of CsA in the nervous system is characterized by its robust neuroprotective and anti-inflammatory effects, which have been studied across various models of neurological damage and neurodegeneration:
Cerebral Ischemia and Reperfusion Injury (IRI): Brain injury often involves ischemia followed by reperfusion, which induces oxidative damage, inflammation, and enlargement of the infarct area. Within the first few minutes of reperfusion, reactive oxygen species (ROS), calcium (Ca2+) overload, and rapid pH correction induce the opening of the mitochondrial permeability transition pore (mPTP). By inhibiting CypD, a key regulator of the mPTP, CsA provides significant neuroprotection and decreases infarct size [1].
Neurodegenerative Diseases: The neuroprotective mechanisms of CsA are highly relevant to diseases characterized by mitochondrial dysfunction and excitotoxicity:
- Alzheimer's Disease (AD): CsA and CypD inhibition protect against amyloid-beta (Aβ)-mediated mitochondrial damage. Suppressing mPTP opening restores mitochondrial function, prolongs the lifespan of neurons, and improves learning and cognitive functions [1].
- Parkinson's Disease (PD): Increased levels of CypD and subsequent mPTP opening are associated with PD. Inhibition or deletion of CypD delays disease onset and extends survival in PD models [1].
- Amyotrophic Lateral Sclerosis (ALS): ALS pathogenesis involves elevated Ca2+ concentrations in motor neurons due to excessive glutamate receptor stimulation, leading to Ca2+ overload and mPTP opening. Targeting CypD with CsA presents a strategy to prevent motor neuron death. Additionally, extracellular CypA acts as a mediator of neuroinflammation in ALS, exerting toxic effects on motor neurons; CsA derivatives (such as MM218) have been shown to reduce this neuroinflammation and extend survival [1].
3. Molecular Mechanism of Action
CsA exerts its diverse pharmacological effects through distinct molecular mechanisms depending on the cyclophilin isoform it targets:
Inhibition of the mPTP (Neuroprotection): The primary mechanism of CsA-mediated neuroprotection is the inhibition of mitochondrial CypD. Under conditions of cellular stress, damage, or mitochondrial Ca2+ overload (common in brain injury and neurodegeneration), a non-specific pore in the inner mitochondrial membrane (IMM)—the mPTP—opens. This allows the passage of solutes up to 1.5 kDa, leading to the loss of IMM potential, uncoupling of oxidative phosphorylation, ATP depletion, mitochondrial swelling, and the release of apoptogenic proteins. CsA binds to CypD, preventing it from facilitating mPTP opening, thereby halting the cascade that leads to autophagy, apoptosis, and necrotic cell death [1].
Modulation of Neuroinflammation: Extracellular CypA initiates pro-inflammatory cascades by activating the CD147 (EMMPRIN) receptor, which drives chemotaxis, vascular inflammation, and blood-brain barrier (BBB) breakdown. CsA and its cell-impermeable derivatives bind to extracellular CypA, blocking its interaction with CD147 and thereby reducing neuroinflammation [1].
Immunosuppression (Calcineurin Pathway): CsA binds to cytosolic CypA and endoplasmic reticulum-resident CypB. The resulting binary CsA/Cyp complex acts as a "molecular glue" that interacts with and inhibits the phosphatase activity of calcineurin. This prevents the dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NF-AT), ultimately blocking interleukin-2 (IL-2) activation and triggering immunosuppression [1] [2].
4. Structure-Activity Relationship (SAR)
CsA is a pan-cyclophilin inhibitor that binds to the highly conserved cyclophilin-like domain (CLD) present in all 17 human cyclophilin isoforms. The active site for cis-trans isomerization is located on the barrel surface of the CLD. CsA targets specific binding pockets within this active site:
Binding Affinity and Calcineurin Inhibition: The inhibition of PPIase activity by CsA shows an IC50 of 25 nM for CypA and 84 nM for CypB. Interestingly, the CypB/CsA complex inhibits calcineurin 13-fold more potently (Ki < 21 nM) compared to the CypA/CsA complex (Ki = 336 nM) [1].
Pocket Interactions: The (4R)-4[(E)-2-butenyl]-4,N-dimethyl-L-threonine (Bmt) residue of CsA targets the S1 pocket of the cyclophilin active site. Additionally, the second residue of CsA binds to the S2 pocket, which contains specific "gatekeeper" residues (e.g., Lys82 in CypA, Thr116 in CypC) that dictate binding tolerance [1].
Non-Immunosuppressive Derivatives: Because the immunosuppressive effect of CsA is dependent on the ternary complex formation with calcineurin rather than the inhibition of PPIase activity itself, structural modifications to CsA have successfully uncoupled these two functions. Derivatives such as NIM-811, SCY-635, alisporivir (Debio025), and rencofilstat (CRV-431) have been developed. These analogs retain the ability to inhibit cyclophilins (including CypD) and block mPTP opening but do not inhibit calcineurin, rendering them non-immunosuppressive [1].
5. Current Limitations
The translation of CsA into a standard neuroprotective therapy for brain injury and neurodegeneration faces several significant hurdles:
Adverse Side Effects: The traditional formulation of CsA causes profound immunosuppression, increasing the host's susceptibility to opportunistic infections [2]. Furthermore, clinical use of calcineurin inhibitors is associated with severe toxicities, including nephrotoxicity, hepatotoxicity, and arterial hypertension [1] [3].
Poor Pharmacokinetics and BBB Penetration: As a macrocyclic peptide, CsA possesses troublesome drug-like properties, including poor aqueous solubility, low oral bioavailability, and a high potential for drug-drug interactions. Crucially for neuroprotection, the transport of CsA across the blood-brain barrier (BBB) is highly restricted because it is a substrate for the multidrug efflux transporter P-glycoprotein [1].
Lack of Isoform Selectivity: CsA is a non-selective pan-cyclophilin inhibitor. Because different cyclophilin isoforms have distinct, sometimes opposing, physiological roles (e.g., CypB overexpression is neuroprotective against oxidative stress, whereas CypA and CypD promote pathology in AD), non-selective inhibition can lead to unwanted off-target effects [1].
6. Future Perspectives
To overcome the limitations of traditional CsA, future therapeutic strategies are heavily focused on medicinal chemistry and targeted drug design:
Isoform-Selective Inhibitors: Achieving selectivity among cyclophilins is challenging due to the highly conserved CLD. However, researchers are exploiting less conserved regions, such as the "three o'clock" pocket and specific S2 gatekeeper residues. For example, newly designed macrocyclic inhibitors utilize hydrogen bonding with CypD-specific residues (Lys118 and Ser123) to achieve up to 100-fold selectivity for CypD over CypA, offering a highly targeted approach for mPTP inhibition without systemic off-target effects [1].
Non-Immunosuppressive and Compartment-Specific Analogs: The continued clinical development of non-immunosuppressive CsA analogs (e.g., NIM-811, alisporivir) holds promise for treating mitochondrial dysfunction in the brain without compromising the immune system. Additionally, cell-impermeable derivatives (such as MM218) that exclusively target extracellular cyclophilins are being explored to specifically combat neuroinflammation [1].
Improving CNS Delivery: Future research must address the pharmacokinetic limitations of CsA. Developing synthetic small-molecule inhibitors that bypass P-glycoprotein efflux, or utilizing novel delivery systems (e.g., liposomal or nanoparticle-mediated delivery), will be essential to achieve therapeutic concentrations of cyclophilin inhibitors in the brain for the effective management of traumatic brain injury and neurodegenerative diseases [1].
